Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
JoVE Journal
Developmental Biology

A subscription to JoVE is required to view this content.
You will only be able to see the first 20 seconds.

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
 

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Article doi: 10.3791/58140
October 3rd, 2018

Summary October 3rd, 2018

We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.

Transcript

Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
simple hit counter